Menu
Menu
Alembic Pharmaceuticals has secured USFDA approval for its Divalproex Sodium Delayed-Release Capsules, offering an affordable alternative to the brand-name drug Depakote. This approval expands Alembic's portfolio in the anti-epileptic market, with significant growth potential. Discover more about the impact of this approval and the company's financial performance.
Glenmark Pharmaceuticals has launched its Lacosamide Oral Solution, a bioequivalent to Vimpat® Oral Solution, offering a more affordable treatment option for partial-onset seizures. This new product enhances access to epilepsy care, with the same therapeutic efficacy as the branded version, making it a valuable option for patients and healthcare providers.